A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE4 trial investigates Candidiasis, Oral and HIV Infections and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Baltimore, United States, Boston, United States, Buffalo, United States, Chapel Hill, United States, Chicago, United States, Cincinnati, United States, Cleveland, United States, Columbus, United States, Denver, United States and 22 more location s